echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > The first domestically-made mRNA COVID-19 vaccine is close to phase III clinical trials, and will achieve a "zero" breakthrough in China's mRNA vaccine

    The first domestically-made mRNA COVID-19 vaccine is close to phase III clinical trials, and will achieve a "zero" breakthrough in China's mRNA vaccine

    • Last Update: 2021-04-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The epidemic is raging, and the process of mRNA vaccines on the cusp of the storm has been closely watched by the world.


    Recently, in an interview, Dr.


    In May, it will work closely with Tigermed to carry out overseas phase III clinical trials.


    At the same time, Aibo Bio-Bio also announced last week that it has completed a total of 600 million yuan of B round of financing.


    fund

    The investment will accelerate the development of the new crown vaccine and its use in the construction of industrial bases.


    Achieve "zero" breakthrough in China's mRNA vaccine

    Achieve "zero" breakthrough in China's mRNA vaccine

    mRNA, or Messenger RNA (messenger ribonucleic acid), is a messenger that transfers genetic information from DNA to protein, and provides instructions for human cells to produce target proteins (antigens), thereby activating the human immune response and resisting the corresponding virus.


    immunity

    Up to now, two mRNA vaccines have been approved globally, namely BNT162b2 developed by BioNTech in Germany and Pfizer and mRNA-1273 developed by Moderna in the United States.


    However, the storage and transportation temperature conditions of the two are relatively harsh, requiring minus -70 degrees (BNT162b2) and -20 degrees (mRNA-1273) respectively.


    Aibo Biological is one of the earliest companies engaged in mRNA drug research and development in China.


    "Whether it is an in vivo animal experiment or a clinical experiment, from the results we got, the domestic ARCoV vaccine product is completely comparable to the two overseas mRNA vaccines.


    SARS-CoV-2 vaccine can elicit a protective immune response in mice and non-human primates

    SARS-CoV-2 vaccine can cause a protective immune response in mice and non-human primates SARS-CoV-2 vaccine can cause a protective immune response in mice and non-human primates

    It is reported that the first two phases of ARCoV clinical data are relatively satisfactory.


    For specific countries selected for phase III clinical trials, or South America first, "will take into account the local epidemic situation, and countries that lack research and development capabilities and vaccine supply will give priority to them.


    Compared with Pfizer vaccine, the difference of ARCoV is that it can be stored at 2-8 degrees Celsius.


    Compared with other types of vaccines, the biggest advantage of mRNA vaccines lies in the short production links and R&D cycle, relatively simple process, and rapid production.


    According to news in December 2020, Watson Bio is mainly responsible for the industrialization of ARCoV.


    Target virus mutations, or complement existing vaccines

    Target virus mutations, or complement existing vaccines

    Judging from the current situation, due to constant mutations, the struggle against the new crown epidemic in countries around the world is long-lasting.


    However, InBev believes that in addition to the excellent preventive effect of the mRNA vaccine used alone , it can also form a good complement to the existing vaccines.
    For example, to increase cellular immunity for inactivated virus vaccines; for adenovirus vector vaccines for a second shot.

    prevention

    "MRNA vaccines are the fastest in the development and production of mutant strains.
    Cross-use is the effect of 1+1>2.
    This can quickly and effectively resist the mutated new crown epidemic.
    "

    At the 2nd Vaccine and Health Conference held in Chengdu recently, Academician Gao Fu, director of the China Center for Disease Control and Prevention, also stated that in view of the existing vaccine protection rate problems, the vaccination procedure can be optimized (increase the dose, change the dose, change the interval, etc.
    ) ; Consider the mixed vaccination of different technical routes to learn from each other.

    Compared with traditional biotechnology, the advantages of mRNA application in vaccines are flexibility and speed.
    Traditional vaccine research and development technology often takes a long time to produce and purify proteins and produce vaccines, while artificially synthesized mRNA is inserted into genetic genes to change.
    Its target enables it to produce specific antibodies.
    Therefore, mRNA technology also brings unlimited reveries to the prevention and treatment of AIDS and cancer.

    At present, Abbio has established a rich product pipeline, and the therapeutic areas cover tumor immunity , infectious disease prevention, various diseases caused by protein expression or lack of function, general-purpose and personalized tumor vaccines, etc.

    Tumor Immunity Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.